Search NTRA
Natera, Inc.
Nasdaq · CIK 1604821
Last close410.35
Daily change+1.88 (0.46%)
10 Years gain+3515.42%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NTRA · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
71.6Momentum
45.8Acceleration
67.5Confidence
91.0Annual Revenue13
Quarterly Revenue53
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality20.3 / 25
Capital Efficiency6.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 3.5799 percentage points.
ROIC expansionROIC improved by 93.2181 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM50.24%OK
Revenue CAGR 3Y41.14%OK
Gross Margin63.97%OK
Operating Margin-14.58%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-52.35%OK
Incremental Operating Margin 3Y6.06%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.33%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.31B | $1.49B | -$309.91M | $215.30M | $109.11M | 64.67% | -13.44% | 4.73% | -47.81% | 136.72M |
| 2025 FY Dec 31, 2024 | $1.70B | $1.02B | -$222.29M | $135.66M | $69.24M | 60.3% | -13.1% | 4.08% | -73.66% | 124.72M |
| 2025 FY Dec 31, 2023 | $1.08B | $492.74M | -$446.25M | -$246.96M | -$286.15M | 45.52% | -41.22% | -26.43% | -272.87% | 115M |
| 2024 FY Dec 31, 2022 | $820.22M | $363.97M | -$541.04M | -$431.50M | -$479.20M | 44.37% | -65.96% | -58.42% | -787.82% | 98.41M |
| 2023 FY Dec 31, 2021 | $625.49M | $307.07M | -$468.17M | -$335.24M | -$376.27M | 49.09% | -74.85% | -60.16% | n/a | 90.56M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.59B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054525, 0001104659-25-107976 |
| Revenue Growth TTM | 50.24% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054525, 0001104659-25-107976 |
| Revenue CAGR 3Y | 41.14% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-020881 |
| Revenue CAGR 5Y | 42.61% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-020881 |
| Gross Profit CAGR 3Y | 60.02% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-020881 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-054525, 0001104659-25-107976 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 63.97% | Gross Profit / Revenue | OK | 0001628280-26-054525, 0001104659-25-107976 |
| Operating Margin | -14.58% | Operating Income / Revenue | OK | 0001628280-26-054525, 0001104659-25-107976 |
| ROIC | -52.35% | NOPAT / Average Invested Capital | OK | 0001628280-26-054525, 0001104659-25-107976 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054525 |
| Current Ratio | 3x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 13.59x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-054525 |
| Revenue per Diluted Share | $18.06 | Revenue / Diluted Shares | OK | 0001628280-26-054525, 0001104659-25-107976 |